Premium
[P4–025]: MEMORY AND BRAIN AMYLOID AND TAU EFFECTS OF CURCUMIN IN NON‐DEMENTED ADULTS: A DOUBLE‐BLIND, PLACEBO‐CONTROLLED 18‐MONTH TRIAL
Author(s) -
Small Gary W.,
Siddarth Prabha,
Ercoli Linda,
Wong KoonPong,
Martinez Jacqueline,
Emerson Natacha D.,
Merrill David A.,
Satyamurthy Nagichettiar,
Huang SungCheng,
Li Zhaoping,
Heber David,
Barrio Jorge R.
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.1889
Subject(s) - curcumin , placebo , visual memory , posterior cingulate , psychology , medicine , amygdala , audiology , neuroscience , functional magnetic resonance imaging , cognition , pathology , pharmacology , alternative medicine
channel blockers and beta blockers; IMPmanufacture: sourcing and over capsulation of study drug and matching placebo and independently establishing blindedness and stability testing of the over encapsulated repurposed agent; safety monitoring and pharmacovigilance. Conclusions: NILVAD is an example of an investigator driven repurposing program for an antihypertensive in AD. The NILVAD trial provides multiple learnings that can be captured and help inform future efforts in this challenging area of drug discovery.